{"id":"https://genegraph.clinicalgenome.org/r/f970a356-e17f-4490-8cfe-a2be08c20379v1.0","type":"EvidenceStrengthAssertion","dc:description":"TRAF7 is a known mediator of the MAPK and NFKB signaling pathways and is involved in multiple biologic processes, such as ubiquitination. *TRAF7* was first reported in relation to autosomal dominant syndromic complex neurodevelopmental disorder in 2018 (Tokita et al., PMID: 29961569). This is a multisystemic developmental disorder with developmental delay/intellectual disability, variable cardiac and digital anomalies, and recognizable facial features. Some patients may have autism spectrum disorder, seizures, hearing loss or ocular abnormalities. Thirteen *de novo* missense variants that have been reported in 16 probands in 2 publications (PMIDs: 29961569, 32376980) are included in this curation. More genetic evidence is available in the literature (PMIDs: 34513876, 37067385, 38569228, 38612512) but the maximum score for genetic evidence (12 points) has been reached. Several variants are recurrent (including p.Arg655Gln and p.Phe617Leu), and most cluster within the WD40 repeats of the TRAF7 protein, suggesting dominant-negative and/or gain-of-function effects. \n\nThis gene-disease relationship is also supported by zebrafish and xenopus *traf7* model systems (PMID: 37043537), and functional studies demonstrating transcriptional changes and altered ERK signaling in the presence of pathogenic *TRAF7* variants (PMID: 29961569, 32376980). \n\nIn summary, there is definitive evidence supporting the relationship between *TRAF7* and autosomal dominant syndromic complex neurodevelopmental disorder. This has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time. This classification was approved by the ClinGen Intellectual Disability and Autism Gene Curation Expert Panels on the meeting date September 6, 2023 (SOP Version 9).\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/f970a356-e17f-4490-8cfe-a2be08c20379","GCISnapshot":"https://genegraph.clinicalgenome.org/r/c6291da3-f236-4abe-ba39-ed00366e894a","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/c6291da3-f236-4abe-ba39-ed00366e894a_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10006","date":"2023-09-06T19:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/c6291da3-f236-4abe-ba39-ed00366e894a_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10006","date":"2024-09-19T21:16:53.230Z","role":"Publisher"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c6291da3-f236-4abe-ba39-ed00366e894a_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/eb9438ed-1eb1-451d-913d-b2d2f1601027","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/eb9438ed-1eb1-451d-913d-b2d2f1601027_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32376980","allele":{"id":"https://genegraph.clinicalgenome.org/r/58c6608f-d63e-48ce-8a0f-b5721e42f640","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032271.3(TRAF7):c.1148A>C (p.Gln383Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA394327633"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/502a08a9-032f-4d41-8b77-041cc81638d7","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/502a08a9-032f-4d41-8b77-041cc81638d7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32376980","allele":{"id":"https://genegraph.clinicalgenome.org/r/f05f12d3-168b-470c-8d7b-be0bf93c50c7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032271.3(TRAF7):c.1097C>T (p.Ser366Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA394327447"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/c4e562e3-629e-4ef5-a427-c1da8500d2af","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c4e562e3-629e-4ef5-a427-c1da8500d2af_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32376980","allele":{"id":"https://genegraph.clinicalgenome.org/r/78b10ffc-63c4-40ed-8b85-00cc59f29b88","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032271.3(TRAF7):c.1975G>T (p.Gly659Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA394336130"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/5da73a35-b74c-49a6-92eb-1345f842d84c","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5da73a35-b74c-49a6-92eb-1345f842d84c_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Variant is located in WD40 domain of the protein. Phosphorylation of ERK1/2 was reduced in mutant-transfected cells relative to wild-type. This reduction was statistically significant with TNFa stimulation for cells expressing the p.Arg655Gln variant (PMID: 29961569).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/5da73a35-b74c-49a6-92eb-1345f842d84c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29961569","allele":{"id":"https://genegraph.clinicalgenome.org/r/ac46e9f8-433e-4911-8e71-78d40468b1ec","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032271.3(TRAF7):c.1964G>A (p.Arg655Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA394336081"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/945a7290-6d42-4f19-81d5-b3725a687251","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/945a7290-6d42-4f19-81d5-b3725a687251_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32376980","allele":{"id":"https://genegraph.clinicalgenome.org/r/a25e10eb-36be-4d5d-ac64-6ed2916eb55b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032271.3(TRAF7):c.1936G>C (p.Val646Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA394336027"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/88b9ce59-1352-4e61-81fb-e88cf11f72fe","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/88b9ce59-1352-4e61-81fb-e88cf11f72fe_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Variant is located in WD40 domain of the protein. Phosphorylation of ERK1/2 was reduced in mutant-transfected cells relative to wild-type. This reduction was statistically significant with TNFa stimulation for cells expressing the p.Arg655Gln variant (PMID: 29961569).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/88b9ce59-1352-4e61-81fb-e88cf11f72fe_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29961569","allele":{"id":"https://genegraph.clinicalgenome.org/r/ac46e9f8-433e-4911-8e71-78d40468b1ec"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/40ae1867-ea54-4d2e-9dbb-c0d9fc4d4406","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/40ae1867-ea54-4d2e-9dbb-c0d9fc4d4406_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32376980","allele":{"id":"https://genegraph.clinicalgenome.org/r/0c8cdfcd-a4f4-4e39-b37d-200053f795f0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032271.3(TRAF7):c.1223G>A (p.Gly408Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA394328223"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/71d8812a-21b9-44d7-a3cb-6d8b400d8bb9","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/71d8812a-21b9-44d7-a3cb-6d8b400d8bb9_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The variant is located in WD40 domain of the protein. Phosphorylation of ERK1/2 was reduced in mutant-transfected cells relative to wild-type. This reduction was statistically significant with TNFa stimulation for cells expressing the p.Arg655Gln variant (PMID: 29961569).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/71d8812a-21b9-44d7-a3cb-6d8b400d8bb9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29961569","allele":{"id":"https://genegraph.clinicalgenome.org/r/ac46e9f8-433e-4911-8e71-78d40468b1ec"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/abe61713-d520-44e0-875d-7b81fbaf8c80","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/abe61713-d520-44e0-875d-7b81fbaf8c80_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Whole transcription analysis and expression of 17 candidate target genes assessed by qRT-PCR using skin fibroblast RNA from the patient, with and without TNFα treatment, suggest that this TRAF7 variant causes an alteration of the signaling pathway that is activated as a response to TNFα ligand (PMID: 32376980).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/abe61713-d520-44e0-875d-7b81fbaf8c80_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32376980","allele":{"id":"https://genegraph.clinicalgenome.org/r/12996247-3ca1-4bed-b46b-a068675947ac","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032271.3(TRAF7):c.1204C>G (p.Leu402Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA394328073"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/8efb3c00-9862-4952-8d7e-55491d35187b","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8efb3c00-9862-4952-8d7e-55491d35187b_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Variant is located in WD40 domain of the protein. Phosphorylation of ERK1/2 was reduced in mutant-transfected cells relative to wild-type. This reduction was statistically significant with TNFa stimulation for cells expressing the p.Thr601Ala variant (PMID: 29961569).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/8efb3c00-9862-4952-8d7e-55491d35187b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29961569","allele":{"id":"https://genegraph.clinicalgenome.org/r/bcbb4ce6-18f2-4bce-ac2f-ffbcbf38ae00","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032271.3(TRAF7):c.1801A>G (p.Thr601Ala)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/587686"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/8df9c9b5-b85f-4b9c-930c-c5eb86229ce7","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8df9c9b5-b85f-4b9c-930c-c5eb86229ce7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32376980","allele":{"id":"https://genegraph.clinicalgenome.org/r/6af2f192-a7aa-402e-8d3a-888278e9baf8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032271.3(TRAF7):c.1849T>C (p.Phe617Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA394335798"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/1e1f4587-cb77-44b0-8b38-e60e9caa4ee8","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1e1f4587-cb77-44b0-8b38-e60e9caa4ee8_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Whole transcription analysis and expression of 17 candidate target genes assessed by qRT-PCR using skin fibroblast RNA from the patient, with and without TNFα treatment, suggest that the TRAF7 variant causes an alteration of the signaling pathway that is activated as a response to TNFα ligand (Figure 5)","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/1e1f4587-cb77-44b0-8b38-e60e9caa4ee8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32376980","allele":{"id":"https://genegraph.clinicalgenome.org/r/ac46e9f8-433e-4911-8e71-78d40468b1ec"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/5776bc4d-b267-479e-82ef-af220b9e43dd","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5776bc4d-b267-479e-82ef-af220b9e43dd_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Phosphorylation of ERK1/2 was reduced in mutant-transfected cells relative to wild-type. This reduction was statistically significant with TNFa stimulation for cells expressing the p.Arg371Gly variant (PMID: 29961569).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/5776bc4d-b267-479e-82ef-af220b9e43dd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29961569","allele":{"id":"https://genegraph.clinicalgenome.org/r/1510a245-3a34-4090-8257-4694bcb57970","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032271.3(TRAF7):c.1111C>G (p.Arg371Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA394327526"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/91fa6575-5a9e-493a-b025-f66c31b06b73","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/91fa6575-5a9e-493a-b025-f66c31b06b73_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Whole transcription analysis and expression of 17 candidate target genes assessed by qRT-PCR using skin fibroblast RNA from the patient, with and without TNFα treatment, suggest that this TRAF7 variant causes an alteration of the signaling pathway that is activated as a response to TNFα ligand (PMID: 32376980).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/91fa6575-5a9e-493a-b025-f66c31b06b73_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32376980","allele":{"id":"https://genegraph.clinicalgenome.org/r/9daec5b1-4912-4b0f-952a-152abdd63095","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032271.3(TRAF7):c.1555C>T (p.Leu519Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA394333087"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/be68cfc8-7f2f-423e-b801-a2bd9c167511","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/be68cfc8-7f2f-423e-b801-a2bd9c167511_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29961569","allele":{"id":"https://genegraph.clinicalgenome.org/r/e456b2cd-e952-4fd6-84cf-6527e057e249","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032271.3(TRAF7):c.1036A>G (p.Lys346Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/587687"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/97357dff-d419-495e-9e8a-35a34ef21a94","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/97357dff-d419-495e-9e8a-35a34ef21a94_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32376980","allele":{"id":"https://genegraph.clinicalgenome.org/r/9b1ca559-5341-421e-9ea1-681c11645d68","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_032271.3(TRAF7):c.1873C>G (p.Leu625Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA394335867"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/c6291da3-f236-4abe-ba39-ed00366e894a_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c6291da3-f236-4abe-ba39-ed00366e894a_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2c84e042-61c6-4b9b-b53e-03d2b6040740","type":"EvidenceLine","dc:description":"Downgraded to 0.5 for non-mammalian model","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/46c8c7b7-ec0c-43d0-9f86-0093ae1df781","type":"Finding","dc:description":"Overexpression and Morpholino/CRISPR/Cas9 mediated knockdown of traf7; Xenopus model shows cardiac, craniofacial and kidney defects similar to those seen in humans with pathogenic TRAF7 variants; the Xenopus mutants also displayed the classic features of ciliopathy: curved body axis, hydrocephaly, and kidney cysts.\"","dc:source":"https://pubmed.ncbi.nlm.nih.gov/37043537","rdfs:label":"Knockdown and overexpression of traf7 in Xenopus","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/68c9fed8-4cdc-441d-82cd-33c5a0a2e952","type":"EvidenceLine","dc:description":"Downgraded to 0.5 for non-mammalian model","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/05c22800-4868-4585-93f3-2000358a2df0","type":"Finding","dc:description":"Morpholino-mediated knockdown; zebrafish model shows cardiac, craniofacial and kidney defects similar to those seen in humans with pathogenic TRAF7 variants; the zebrafish mutants also displayed the classic features of ciliopathy: curved body axis, hydrocephaly, and kidney cysts.\"","dc:source":"https://pubmed.ncbi.nlm.nih.gov/37043537","rdfs:label":"Knockdown of traf7 in zebrafish","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":1}],"evidenceStrength":"Definitive","sequence":8995,"specifiedBy":"GeneValidityCriteria9","strengthScore":13,"subject":{"id":"https://genegraph.clinicalgenome.org/r/Rw871vh0MvM","type":"GeneValidityProposition","disease":"obo:MONDO_0800439","gene":"hgnc:20456","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_c6291da3-f236-4abe-ba39-ed00366e894a-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}